NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
PARIS and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the…
3,071€
7,45%
Echtzeit-Aktienkurs Nanobiotix S.A.
Bid:
Ask:
Nachrichten zur Nanobiotix S.A. Aktie
NANOBIOTIX to Participate in Multiple Investor Conferences in November
~ Guggenheim’s Inaugural Healthcare Innovation Conference, Nov 11-13 ~…
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the…
Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call Transcript
…
Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript
…
Nanobiotix to Present at Upcoming Investor Conferences in March
PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the…